AbbVie obtains licence for Turnstone Biologics ’ oncolytic viral immunotherapies

AbbVie has entered a research, option and licence agreement with clinical-stage immuno-oncology company Turnstone Biologics for oncolytic viral immunotherapies.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news